TheraVet starts its US operations in its Texas-based subsidiary

November 7th 2019

TheraVet S.A., the specialist of the osteo-articular diseases of small companion animals, announced today the incorporation of its Texas-based subsidiary and the launch of its activities in the United States of America
The first objective of TheraVet USA is to conduct a clinical confirmation study in accordance with the FDA's Center for Veterinary Medicine standards. The aim of this study is to confirm the safety and efficacy of VISCO-VET, a new generation hyaluronan-based visco-antalgic, in reducing the pain and lameness associated with osteoarthritis in dogs. Current treatments for osteoarthritis in dogs are either limited to pain management (NSAIDs, corticosteroids), without treating the disease itself, or are very invasive (surgery). With VISCO-VET, TheraVet aims to offer a safe, non-invasive and efficacy-proven solution for dogs suffering from osteoarthritis. Please discover the press release here.